Online Inquiry
Therapeutic Antibody Development for Prostate Cancer
Therapeutic antibodies are drugs that use antibodies to bind to tumor antigens, thereby targeting cancer and achieving a therapeutic effect. At Alfa Cytology, our mission is to provide one-stop therapeutic antibody development services for prostate cancer.
Introduction to Therapeutic Antibody
Therapeutic antibodies are drugs that use antibodies, one of the main players in our immune system inherent in our body. By making use of the specificity by which each antibody recognizes only one antigen, pinpointed attacks on specific antigens are possible. Prostate cancer is highly amenable to therapeutic antibody targeting given the existence of prostate-specific targets and the natural history and localization of metastatic disease.
Fig.
1 Possible antigen targets for T cell activation with bsAbs in prostate cancer. (Heitmann, J. S., et
al. 2021)
Advantages of Therapeutic Antibody
The combination of therapeutic antibodies with other therapeutic modalities is expected to further improve the response to therapy and overall survival of prostate patients, giving them hope for a cure. These findings highlight the importance of therapeutic antibodies for prostate cancer therapy.
Target specificity
Therapeutic antibodies accurately recognize and bind to specific antigens, and this high degree of specificity reduces the impact on normal cells, thereby improving the effectiveness of treatment.
Minor side effects
Due to the highly targeted nature of therapeutic antibodies, they usually do not affect non-target cells, which reduces damage to normal cells and tissues, thus reducing side effects.
Long half-life
Therapeutic antibodies usually have a long half-life related to their structure. The Fc region of the antibody interacts with t Fc receptor, which contributes to the recycling and reutilization of the antibody in the body.
Therapeutic Antibody Development for Prostate Cancer
Progress in the understanding of molecular events in prostate cancer development and progression as well as the identification of tumor antigens has led to the development of different targeted therapeutic approaches, including the use of therapeutic antibodies.
| Name | Target | Phase | Company | Country |
| ARX517 | PSMA | Phase I | Johnson & Johnson | USA |
| Acapatamab | PSMA & CD3 | Phase I | Amgen | USA |
| Enoblituzumab | B7-H3 | Phase II | MacroGenics | USA |
| Pluvicto | PSMA | Market Approval | Novartis | USA |
Our Services
Alfa Cytology continuously focuses on therapeutic antibodies research in the field of prostate cancer, aiming to provide comprehensive development services customized to our customers' needs. Our key differentiator is our ability to plan and execute complex development tasks on time, saving our clients development time and costs. As a highly recognized pioneer in the global therapeutic antibody field, we have professional knowledge and extensive experience.
Monoclonal Antibody Development
We provide one-stop monoclonal antibody development services, including complex biotechnological processes for
B-lymphocyte clone selection, hybridoma technology, antibody purification, and subsequent antibody engineering
modifications.
Polyclonal Antibody Development
The development of polyclonal antibodies is the process of immunizing an animal with a specific antigen and
extracting and purifying from the resulting immune response a mixture of multiple antibodies that recognize multiple
epitopes of that antigen.
Bispecific Antibody Development
The development of bispecific cloned antibodies requires the use of recombinant DNA technology or cell fusion and
the need to ensure the correct pairing of the light and heavy chains to form a functional bispecific antibody.
Single Domain Antibody
Development
We provide a one-stop service for single domain antibody development, which mainly includes the process of
extracting, cloning and recombinantly expressing antibody molecules with only heavy chain variable regions.
ADC
Development
The development of ADCs involves combining a cytotoxic drug with a monoclonal antibody via a chemical connector for
targeted delivery, thereby exerting a potent anti-tumor effect on the target cells while reducing toxicity to
healthy cells.
ATC Development
Optimized cutting-edge engineering techniques to facilitate accurate toxin-antibody linkage, preserving the structural integrity and therapeutic functionality of customized antibody-toxin conjugates (ATCs).
Workflow of Therapeutic Antibody Development
Our Advantages
We are committed to providing efficient, innovative and reliable development solutions by leveraging our in-depth professional knowledge, adopting cutting-edge technologies, and enforcing strict quality control standards.
Professional Knowledge
Cutting-Edge Technologies
Quality Control
Nowadays, therapeutic antibodies have become an important research direction in prostate cancer therapy, and more innovative therapeutic antibodies may be applied in the therapy of prostate cancer in the future. We provide one-stop service for therapeutic antibody development. Contact us to learn more about our services.
Reference
- Heitmann, J. S., et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers. 2021, 13(3): 549.
For research use only.